 Chiasma, Inc. CHMA, a clinical, late-stage biopharmaceutical company focused on improving the lives of patients with rare and serious chronic diseases, today announced its entry into a revenue interest financing agreement with HealthCare Royalty Partners HCR for up to 75 million to support the ongoing development and planned commercial launch of its investigational octreotide capsules product candidate, trade-named MYCAPSSA, for the maintenance treatment of adults with acromegaly. Under the terms of the agreement, Chiasma will receive 25 million from HCR on April 14, 2020 and is entitled to receive an additional 25 million upon the U.S. Food and Drug Administration FDA approval of MYCAPSSA and an additional 15 million upon the availability of commercial drug supply and first commercial sale of MYCAPSSA. 